Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 362

1.

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN; BADBIR study group, the BSTOP study group and the PSORT consortium.

J Allergy Clin Immunol. 2018 Dec 19. pii: S0091-6749(18)32780-5. doi: 10.1016/j.jaci.2018.11.038. [Epub ahead of print]

PMID:
30578879
2.

Major Histocompatibility Complex and Psoriasis.

Zhou F, Zhang X.

J Investig Dermatol Symp Proc. 2018 Dec;19(2):S79-S80. doi: 10.1016/j.jisp.2018.09.006.

PMID:
30471757
3.

How ERAP1 and ERAP2 Shape the Peptidomes of Disease-Associated MHC-I Proteins.

López de Castro JA.

Front Immunol. 2018 Oct 30;9:2463. doi: 10.3389/fimmu.2018.02463. eCollection 2018. Review.

4.

Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis.

Yan D, Ahn R, Leslie S, Liao W.

Dermatol Ther (Heidelb). 2018 Dec;8(4):593-604. doi: 10.1007/s13555-018-0266-x. Epub 2018 Oct 20.

5.

Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis.

Polachek A, Al-Johani R, Li S, Ye JY, Chandran V, Gladman D.

Semin Arthritis Rheum. 2018 Aug 24. pii: S0049-0172(18)30280-4. doi: 10.1016/j.semarthrit.2018.08.005. [Epub ahead of print]

PMID:
30243758
6.

Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Galluzzo M, D'Adamio S, Campione E, Bianchi L, Talamonti M.

Mol Diagn Ther. 2018 Dec;22(6):717-721. doi: 10.1007/s40291-018-0354-8.

PMID:
30076588
7.

The Psoriasis Risk Allele HLA-C*06:02 Shows Evidence of Association with Chronic or Recurrent Streptococcal Tonsillitis.

Haapasalo K, Koskinen LLE, Suvilehto J, Jousilahti P, Wolin A, Suomela S, Trembath R, Barker J, Vuopio J, Kere J, Jokiranta TS, Saavalainen P.

Infect Immun. 2018 Sep 21;86(10). pii: e00304-18. doi: 10.1128/IAI.00304-18. Print 2018 Oct.

PMID:
30037793
8.

ERAP1 and HLA-C*06 are strongly associated with the risk of psoriasis in the population of northern Poland.

Stawczyk-Macieja M, Szczerkowska-Dobosz A, Rębała K, Gabig-Cimińska M, Nowicki RJ, Haraś A, Cybulska L, Kapińska E.

Postepy Dermatol Alergol. 2018 Jun;35(3):286-292. doi: 10.5114/ada.2018.76226. Epub 2018 Jun 18.

9.

Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.

Prinz JC.

Front Immunol. 2018 Apr 30;9:954. doi: 10.3389/fimmu.2018.00954. eCollection 2018. Review.

10.

HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to treatment.

Borroni RG, Costanzo A.

Br J Dermatol. 2018 Apr;178(4):825. doi: 10.1111/bjd.16412. No abstract available.

PMID:
29668091
11.

HLA-C*06:02-independent, gender-related association of PSORS1C3 and PSORS1C1/CDSN single-nucleotide polymorphisms with risk and severity of psoriasis.

Wiśniewski A, Matusiak Ł, Szczerkowska-Dobosz A, Nowak I, Kuśnierczyk P.

Mol Genet Genomics. 2018 Aug;293(4):957-966. doi: 10.1007/s00438-018-1435-4. Epub 2018 Mar 27.

12.

IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.

Bojko A, Ostasz R, Białecka M, Klimowicz A, Malinowski D, Budawski R, Bojko P, Droździk M, Kurzawski M.

Hum Immunol. 2018 Apr;79(4):213-217. doi: 10.1016/j.humimm.2018.02.003. Epub 2018 Feb 15.

PMID:
29454820
13.

Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7.

Qiao M, Li R, Zhao X, Yan J, Sun Q.

Exp Cell Res. 2018 Feb 15;363(2):243-254. doi: 10.1016/j.yexcr.2018.01.014. Epub 2018 Jan 13.

PMID:
29339075
14.

Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis.

Wei WH, Massey J, Worthington J, Barton A, Warren RB.

J Hum Genet. 2018 Mar;63(3):289-296. doi: 10.1038/s10038-017-0350-6. Epub 2017 Dec 19.

PMID:
29259305
15.

The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset.

Wiśniewski A, Matusiak Ł, Szczerkowska-Dobosz A, Nowak I, Łuszczek W, Kuśnierczyk P.

Hum Immunol. 2018 Feb;79(2):109-116. doi: 10.1016/j.humimm.2017.11.010. Epub 2017 Nov 26.

PMID:
29183862
16.

Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.

Raposo I, Carvalho C, Bettencourt A, Da Silva BM, Leite L, Selores M, Torres T.

Eur J Dermatol. 2017 Oct 1;27(5):528-530. doi: 10.1684/ejd.2017.3071. No abstract available.

PMID:
29084639
17.

Genetic factors are stressed variably by onset age-based sample selection in psoriasis: A hint from major histocompatibility complex region-based analysis.

Ye L, Yang C, Dou JF, Wen LL, Wang WJ, Zheng XD, Zuo XB, Zhou FS, Fan X, Zhang XJ.

J Gene Med. 2017 Dec;19(12). doi: 10.1002/jgm.2997. Epub 2017 Nov 28.

PMID:
29076194
18.

Pushing the Envelope in Psoriasis: Late Cornified Envelope Proteins Possess Antimicrobial Activity.

Archer NK, Dilolli MN, Miller LS.

J Invest Dermatol. 2017 Nov;137(11):2257-2259. doi: 10.1016/j.jid.2017.08.026.

19.

Variants at HLA-A, HLA-C, and HLA-DQB1 Confer Risk of Psoriasis Vulgaris in Japanese.

Hirata J, Hirota T, Ozeki T, Kanai M, Sudo T, Tanaka T, Hizawa N, Nakagawa H, Sato S, Mushiroda T, Saeki H, Tamari M, Okada Y.

J Invest Dermatol. 2018 Mar;138(3):542-548. doi: 10.1016/j.jid.2017.10.001. Epub 2017 Oct 12.

20.

Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis.

Prinz JC.

J Invest Dermatol. 2017 Oct;137(10):2053-2058. doi: 10.1016/j.jid.2017.05.023. Review.

Supplemental Content

Loading ...
Support Center